+

WO2012016133A3 - Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 - Google Patents

Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 Download PDF

Info

Publication number
WO2012016133A3
WO2012016133A3 PCT/US2011/045876 US2011045876W WO2012016133A3 WO 2012016133 A3 WO2012016133 A3 WO 2012016133A3 US 2011045876 W US2011045876 W US 2011045876W WO 2012016133 A3 WO2012016133 A3 WO 2012016133A3
Authority
WO
WIPO (PCT)
Prior art keywords
glioblastoma
treatment
kinase inhibitors
ros1 kinase
deficient cancers
Prior art date
Application number
PCT/US2011/045876
Other languages
English (en)
Other versions
WO2012016133A2 (fr
Inventor
Dorre Grueneberg
Ed Harlow
Jun XIAN
Original Assignee
President And Fellows Of Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by President And Fellows Of Harvard College filed Critical President And Fellows Of Harvard College
Publication of WO2012016133A2 publication Critical patent/WO2012016133A2/fr
Publication of WO2012016133A3 publication Critical patent/WO2012016133A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des méthodes et des compositions pour le traitement de tumeurs, notamment des glioblastomes, à l'aide d'inhibiteurs de ROS1. Les cellules cancéreuses sont préférentiellement inhibées par rapport aux cellules normales par l'inhibition de ROS1 kinases tumorales qui sont nécessaires pour la croissance de cellules tumorales, mais pas pour des cellules normales.
PCT/US2011/045876 2010-07-29 2011-07-29 Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53 WO2012016133A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40057810P 2010-07-29 2010-07-29
US61/400,578 2010-07-29

Publications (2)

Publication Number Publication Date
WO2012016133A2 WO2012016133A2 (fr) 2012-02-02
WO2012016133A3 true WO2012016133A3 (fr) 2012-04-26

Family

ID=45530737

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2011/045876 WO2012016133A2 (fr) 2010-07-29 2011-07-29 Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53

Country Status (1)

Country Link
WO (1) WO2012016133A2 (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Families Citing this family (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8563573B2 (en) 2007-11-02 2013-10-22 Vertex Pharmaceuticals Incorporated Azaindole derivatives as CFTR modulators
US8802868B2 (en) 2010-03-25 2014-08-12 Vertex Pharmaceuticals Incorporated Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide
KR20190061096A (ko) 2010-04-22 2019-06-04 버텍스 파마슈티칼스 인코포레이티드 시클로알킬카르복스아미도-인돌 화합물의 제조 방법
AU2012335220B2 (en) 2011-11-11 2017-06-01 Pfizer Inc. 2-thiopyrimidinones
EP3312160B1 (fr) 2011-12-21 2020-03-18 Novira Therapeutics Inc. Agents antiviraux de l'hépatite b
EP3336181B1 (fr) 2012-04-18 2022-01-12 Cell Signaling Technology, Inc. Egfr et ros1 dans le cancer
JP6505013B2 (ja) 2012-08-28 2019-04-24 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミド及びｂ型肝炎の治療のための薬剤としてのその使用
JP6466348B2 (ja) 2013-02-28 2019-02-06 ヤンセン・サイエンシズ・アイルランド・アンリミテッド・カンパニー スルファモイル−アリールアミドおよびｂ型肝炎を処置するための医薬品としてのその使用
WO2014165128A2 (fr) 2013-03-12 2014-10-09 Novira Therapeutics, Inc. Agents antiviraux contre l'hépatite b
US9963452B2 (en) 2013-03-14 2018-05-08 Augusta Pharmaceuticals Inc. Methods, compounds, and compositions for inhibition of ROS
EP2981536B1 (fr) 2013-04-03 2017-06-14 Janssen Sciences Ireland UC Dérivés de n-phenyl-carboxamide et leur utilisation comme médicaments pour le traitement de l'hépatite b
DE102013008118A1 (de) 2013-05-11 2014-11-13 Merck Patent Gmbh Arylchinazoline
JO3603B1 (ar) 2013-05-17 2020-07-05 Janssen Sciences Ireland Uc مشتقات سلفامويل بيرولاميد واستخدامها كادوية لمعالجة التهاب الكبد نوع بي
RS57222B1 (sr) 2013-07-25 2018-07-31 Janssen Sciences Ireland Uc Derivati pirolamida supstituisani sa glioksiamidom i njihova primena kao lekova u tretmanu hepatitisa b
GB201317363D0 (en) 2013-10-01 2013-11-13 Eisai Ltd Novel compounds
ES2968371T3 (es) 2013-10-10 2024-05-09 Eastern Virginia Medical School Derivados de 4-((2-hidroxi-3-metoxibencil)amino) bencenosulfonamida como inhibidores de la 12-lipoxigenasa
JO3554B1 (ar) 2013-10-14 2020-07-05 Eisai R&D Man Co Ltd مركبات كينولين مستبدلة انتقائياً
MX363708B (es) 2013-10-14 2019-03-29 Eisai R&D Man Co Ltd Compuestos de quinolina selectivamente sustituidos.
KR102290189B1 (ko) 2013-10-23 2021-08-17 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 카르복스아미드 유도체 및 ｂ형 간염 치료용 의약으로서의 이의 용도
US10392349B2 (en) 2014-01-16 2019-08-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9181288B2 (en) 2014-01-16 2015-11-10 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
US9169212B2 (en) 2014-01-16 2015-10-27 Novira Therapeutics, Inc. Azepane derivatives and methods of treating hepatitis B infections
MX383447B (es) 2014-02-05 2025-03-14 Novira Therapeutics Inc Combinación de un inhibidor de ensamblaje de cápsido y peginterferón alfa-2a y sus usos para tratar infecciones por virus de la hepatitis b (vhb).
EA035848B1 (ru) 2014-02-06 2020-08-20 Янссен Сайенсиз Айрлэнд Юси Производные сульфамоилпирроламида и их применение в качестве медикаментов для лечения гепатита b
GB201402277D0 (en) 2014-02-10 2014-03-26 Sentinel Oncology Ltd Pharmaceutical compounds
EP3392244A1 (fr) 2014-02-13 2018-10-24 Incyte Corporation Cyclopropylamines en tant qu'inhibiteurs de lsd1
PL3105218T3 (pl) 2014-02-13 2020-03-31 Incyte Corporation Cyklopropyloaminy jako inhibitory lsd1
SMT201900620T1 (it) 2014-02-13 2020-01-14 Incyte Corp Ciclopropilammine come inibitori di lsd1
US9400280B2 (en) 2014-03-27 2016-07-26 Novira Therapeutics, Inc. Piperidine derivatives and methods of treating hepatitis B infections
JP6543268B2 (ja) 2014-04-15 2019-07-10 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ 嚢胞性線維症膜コンダクタンス調節因子が媒介する疾患を処置するための医薬組成物
WO2016007731A1 (fr) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyridines et imidazopyrazines à utiliser en tant qu'inhibiteurs de lsd1
US9695167B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted triazolo[1,5-a]pyridines and triazolo[1,5-a]pyrazines as LSD1 inhibitors
TW201613925A (en) 2014-07-10 2016-04-16 Incyte Corp Imidazopyrazines as LSD1 inhibitors
US9758523B2 (en) 2014-07-10 2017-09-12 Incyte Corporation Triazolopyridines and triazolopyrazines as LSD1 inhibitors
US11299496B2 (en) 2014-07-23 2022-04-12 Northeastern University Ligands for alpha-7 nicotinic acetylcholine receptors and methods of treating neurological and inflammatory conditions
CA2980298A1 (fr) 2015-03-19 2016-09-22 Novira Therapeutics, Inc. Derives d'azocane et d'azonane, et methodes de traitement d'infections provoquees par le virus de l'hepatite b
ES2757948T3 (es) 2015-04-03 2020-04-30 Incyte Corp Compuestos heterocíclicos como inhibidores LSD1
KR20170132326A (ko) 2015-05-05 2017-12-01 화이자 인코포레이티드 2-티오피리미딘온
US10875876B2 (en) 2015-07-02 2020-12-29 Janssen Sciences Ireland Uc Cyclized sulfamoylarylamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
AU2016306555B2 (en) 2015-08-12 2021-01-28 Incyte Holdings Corporation Salts of an LSD1 inhibitor
EP3356328A1 (fr) 2015-09-29 2018-08-08 Novira Therapeutics, Inc. Formes cristallines d'un agent antiviral de l'hépatite b
ES2928164T3 (es) 2015-10-19 2022-11-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
CA3005727A1 (fr) 2015-11-19 2017-05-26 Incyte Corporation Composes heterocycliques de 2-methylbiphenyle-3-yl substitue et compositions pharmaceutiques connexes utiles comme immunomodulateurs
SMT202000694T1 (it) 2015-12-22 2021-03-15 Incyte Corp Composti eterociclici come immunomodulatori
CN109640980A (zh) 2016-04-15 2019-04-16 诺维拉治疗公司 包含壳体装配抑制剂的组合和方法
IL262488B (en) 2016-04-22 2022-08-01 Incyte Corp lsdi inhibitor formulations
AR108396A1 (es) 2016-05-06 2018-08-15 Incyte Corp Compuestos heterocíclicos como inmunomoduladores
US20170342060A1 (en) 2016-05-26 2017-11-30 Incyte Corporation Heterocyclic compounds as immunomodulators
AU2017275657B2 (en) 2016-06-02 2021-08-19 Novartis Ag Potassium channel modulators
EP4137489A1 (fr) 2016-06-20 2023-02-22 Incyte Corporation Composés hétérocycliques en tant qu'immunomodulateurs
MA45669A (fr) 2016-07-14 2019-05-22 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
MA46045A (fr) 2016-08-29 2021-04-28 Incyte Corp Composés hétérocycliques utilisés comme immunomodulateurs
EP3558989B1 (fr) 2016-12-22 2021-04-14 Incyte Corporation Dérivés de triazolo[1,5-a]pyridine en tant qu'immunomodulateurs
LT3558990T (lt) 2016-12-22 2022-12-27 Incyte Corporation Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai
MX391981B (es) 2016-12-22 2025-03-21 Incyte Corp Derivados de benzooxazol como inmunomoduladores.
MA47120A (fr) 2016-12-22 2021-04-28 Incyte Corp Dérivés pyridine utilisés en tant qu'immunomodulateurs
AR110770A1 (es) 2017-01-23 2019-05-02 Cadent Therapeutics Inc Moduladores del canal de potasio
MX388196B (es) 2017-04-26 2025-03-19 Basilea Pharm Int Ag Procesos para la preparacion de furazanobencimidazoles y formas cristalinas de estos.
US11731967B2 (en) 2017-04-28 2023-08-22 Dana-Farber Cancer Institute, Inc. Inhibitors of TRIM33 and methods of use
JP7277431B2 (ja) 2017-07-11 2023-05-19 バーテックス ファーマシューティカルズ インコーポレイテッド ナトリウムチャネルのモジュレーターとしてのカルボキサミド
KR20200143376A (ko) 2018-03-13 2020-12-23 샤이어 휴먼 지네틱 테라피즈 인크. 혈장 칼리크레인 억제제로서의 치환된 이미다조피리딘 및 이의 용도
EP3765011A1 (fr) 2018-03-14 2021-01-20 Janssen Sciences Ireland Unlimited Company Schéma posologique de modulateur d'assemblage de capside
KR20210005593A (ko) 2018-03-23 2021-01-14 유마니티 테라퓨틱스, 인크. 화합물 및 이의 용도
CN112135824B (zh) 2018-03-30 2024-11-05 因赛特公司 作为免疫调节剂的杂环化合物
SG11202011165TA (en) 2018-05-11 2020-12-30 Incyte Corp Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
WO2020047198A1 (fr) 2018-08-31 2020-03-05 Incyte Corporation Sels d'un inhibiteur de lsd1 et leurs procédés de préparation
KR20210060556A (ko) 2018-09-18 2021-05-26 니캉 테라퓨틱스 인코포레이티드 Src 호몰로지-2 포스파타아제 억제제로서의 3-치환된 헤테로아릴 유도체
TWI767148B (zh) 2018-10-10 2022-06-11 美商弗瑪治療公司 抑制脂肪酸合成酶(fasn)
KR20210080446A (ko) 2018-10-22 2021-06-30 카덴트 테라퓨틱스, 인크. 칼륨 채널 조절제의 결정 형태
CA3122093A1 (fr) 2018-12-06 2020-06-11 Constellation Pharmaceuticals, Inc. Modulateurs de trex1
MX2021008661A (es) 2019-01-18 2021-08-19 Astrazeneca Ab Inhibidores de la pcsk9 y metodos de uso de los mismos.
SG11202108079RA (en) 2019-01-24 2021-08-30 Yumanity Therapeutics Inc Compounds and uses thereof
KR20210130753A (ko) 2019-02-22 2021-11-01 얀센 사이언시즈 아일랜드 언리미티드 컴퍼니 Hbv 감염 또는 hbv-유발성 질환의 치료에 유용한 아미드 유도체
WO2020214336A2 (fr) * 2019-03-21 2020-10-22 University Of Virginia Patent Foundation Chimie d'échange soufre-hétérocycle et utilisations associées
AU2020269897A1 (en) 2019-05-06 2021-10-14 Janssen Sciences Ireland Unlimited Company Amide derivatives useful in the treatment of HBV infection or HBV-induced diseases
AR119731A1 (es) 2019-05-17 2022-01-05 Novartis Ag Inhibidores del inflamasoma nlrp3
CA3150434A1 (fr) 2019-08-09 2021-02-18 Incyte Corporation Sels d'un inhibiteur de pd-1/pd-l1
PT4031547T (pt) 2019-09-18 2024-08-27 Takeda Pharmaceuticals Co Inibidores de calicreína plasmática e utilizações dos mesmos
CN114667289A (zh) 2019-09-18 2022-06-24 武田药品工业有限公司 杂芳基血浆激肽释放酶抑制剂
BR112022005826A2 (pt) 2019-09-30 2022-06-21 Incyte Corp Compostos de pirido[3,2-d]pirimidina como imunomoduladores
JP2023500395A (ja) 2019-11-11 2023-01-05 インサイト・コーポレイション Ｐｄ－１／ｐｄ－ｌ１阻害剤の塩及び結晶形態
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
ES2998396T3 (en) 2019-12-06 2025-02-20 Vertex Pharma Substituted tetrahydrofurans as modulators of sodium channels
CN111205303B (zh) * 2020-03-03 2021-04-27 四川大学 噻吩并[2,3-d]嘧啶基异羟肟酸衍生物及其用途
CN115996917A (zh) 2020-05-06 2023-04-21 艾捷斯治疗公司 作为jak2抑制剂的6-杂芳基氧基苯并咪唑和氮杂苯并咪唑
JP2023527379A (ja) * 2020-05-27 2023-06-28 コンステレーション・ファーマシューティカルズ・インコーポレイテッド Ｔｒｅｘ１のモジュレーターとしての置換ベンズアミド
TW202233615A (zh) 2020-11-06 2022-09-01 美商英塞特公司 Ｐｄ—１／ｐｄ—ｌ１抑制劑之結晶形式
WO2022099018A1 (fr) 2020-11-06 2022-05-12 Incyte Corporation Procédé de préparation d'un inhibiteur de pd-1/pd-l1
PE20231438A1 (es) 2020-11-06 2023-09-14 Incyte Corp Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo
TW202241889A (zh) 2020-12-23 2022-11-01 美商雅捷可斯治療公司 作為ｊａｋ２抑制劑之６－雜芳基氧基苯并咪唑及氮雜苯并咪唑
PE20241335A1 (es) 2021-06-04 2024-07-03 Vertex Pharma N-(hidroxialquil (hetero)aril) tetrahidrofurano carboxamidas como moduladores de canales de sodio
JP2024529298A (ja) 2021-07-09 2024-08-06 プレキシウム インコーポレイテッド Ｉｋｚｆ２を調節するアリール化合物及び医薬組成物
WO2023075285A1 (fr) * 2021-10-27 2023-05-04 고려대학교 산학협력단 Composition destinée à la prévention ou au traitement de la maladie de graves comprenant un composé contenant une structure imidazopyridine en tant que principe actif
US11970494B2 (en) 2021-11-09 2024-04-30 Ajax Therapeutics, Inc. 6-heteroaryloxy benzimidazoles and azabenzimidazoles as JAK2 inhibitors
US12162881B2 (en) 2021-11-09 2024-12-10 Ajax Therapeutics, Inc. Forms and compositions of inhibitors of JAK2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140128A2 (fr) * 2008-05-13 2009-11-19 Irm Llc Composés et compositions servant d'inhibiteurs de kinases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140128A2 (fr) * 2008-05-13 2009-11-19 Irm Llc Composés et compositions servant d'inhibiteurs de kinases

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BYUNG SUN PARK ET AL.: "Design, synthesis and biological evaluation of new potent and highly selective ROS1-tyrosine kinase inhibitor", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 16, 2009, pages 4720 - 4723, XP026419064 *
HYUN JUNG JUN ET AL.: "Epigenetic Regulation of c-ROS receptor tyrosine kinase expression in Malignant gliomas", CANCER RESEARCH, vol. 69, no. 6, 2009, pages 2180 - 2184 *
IBRABIM MUSTAFA EL-DEEB ET AL.: "ROS Receptor Tyrosine Kinase: A New Potential target for Anticancer Drugs", MEDICINAL RESEARCH REVIEWS, vol. 31, no. 5, 2011, pages 794 - 818 *
IBRAHIM M. EL-DEEB ET AL.: "Design, synthesis, screening, and molecular modeling study of a new series or ROS1 receptor tyrosine kinase inhibitors", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, vol. 19, no. 19, 2009, pages 5622 - 5626 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9527835B2 (en) 2014-02-13 2016-12-27 Incyte Corporation Cyclopropylamines as LSD1 inhibitors

Also Published As

Publication number Publication date
WO2012016133A2 (fr) 2012-02-02

Similar Documents

Publication Publication Date Title
WO2012016133A3 (fr) Inhibiteurs de la ros1 kinase pour le traitement de glioblastome et d'autres cancers déficients en p53
WO2010141738A3 (fr) Compositions et procédé pour inhiber la croissance d'une tumeur
MX2015007205A (es) Inhibidores de la desmetilasa de histona.
MX360404B (es) Compuestos para inhibir la proliferacion celular en canceres transmitidos por egfr.
NZ718190A (en) Substituted quinazolines for inhibiting kinase activity
WO2013023084A3 (fr) Procédés et compositions pour l'inhibition de la croissance et/ou de la prolifération de cellules tumorales activées par myc
MY160399A (en) Compounds, compositions, and methods for preventing metastasis of cancer cells
WO2011112953A3 (fr) Utilisation d'inhibiteurs d'erbb3 dans le traitement de cancers du sein triples négatifs et de type basal
SA515360657B1 (ar) مثبطات ديميثيلاز هيستون
MY163477A (en) Pyrimidinyl-pyridazinone derivatives
WO2012015914A3 (fr) Modificateurs du récepteur d'hydrocarbure aryle (ahr) en tant que nouveaux produits thérapeutiques anticancéreux
WO2011037643A3 (fr) Compositions et procédés de détection et de traitement de carcinomes de la prostate
TNSN08375A1 (en) Quinazolines for pdk1 inhibition
WO2012170827A3 (fr) Pyrazolopyrimidines et hétérocycles associés comme inhibiteurs de ck2
PH12012500497A1 (en) Substituted (heteroarylmethyl) thiohydantoins as anticancer drugs
MX2011012369A (es) Pirazolopirimidinas y heterociclos relacionados como inhibidores de cinasa.
WO2013093508A3 (fr) Inhibiteurs de la voie wnt
MX2014013090A (es) Derivados de pirrolotriazinona.
PH12014502047B1 (en) Treatment of cancer with tor kinase inhibitors
WO2010104598A3 (fr) Inhibiteurs de la liaison à une protéine kinase
WO2011159685A3 (fr) Inhibition de l'interaction de la protéine wdr5 avec ses partenaires de liaison et méthodes thérapeutiques associées
WO2012135641A3 (fr) Inhibiteurs de kinase aurora et procédés pour les fabriquer et les utiliser
WO2011146568A8 (fr) Prédiction de réponses à un inhibiteur de her
NZ723971A (en) Methods and compositions for treating ewings sarcoma family of tumors
WO2008144507A3 (fr) Inhibiteurs de spirooxindole de kinase de l'aurore

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11813240

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11813240

Country of ref document: EP

Kind code of ref document: A2

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载